Marshall Wace’s Ultralife ULBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$154K Buy
24,435
+13,357
+121% +$90.1K ﹤0.01% 2871
2026
Q1
$72.2K Sell
11,078
-22,971
-67% -$143K ﹤0.01% 2938
2025
Q4
$195K Sell
34,049
-4,033
-11% -$24.9K ﹤0.01% 2603
2025
Q3
$260K Buy
+38,082
New +$288K ﹤0.01% 2482
2025
Q2
Sell
-23,254
Closed -$125K 3201
2025
Q1
$125K Sell
23,254
-9,631
-29% -$65.5K ﹤0.01% 2476
2024
Q4
$245K Buy
32,885
+3,426
+12% +$28.2K ﹤0.01% 2295
2024
Q3
$266K Sell
29,459
-8,524
-22% -$87.9K ﹤0.01% 2198
2024
Q2
$403K Sell
37,983
-5,864
-13% -$62.4K ﹤0.01% 2043
2024
Q1
$386K Sell
43,847
-769
-2% -$6.26K ﹤0.01% 2028
2023
Q4
$304K Buy
+44,616
New +$366K ﹤0.01% 1889
2021
Q3
Sell
-12,234
Closed -$103K 3444
2021
Q2
$103K Sell
12,234
-7,008
-36% -$60.3K ﹤0.01% 2533
2021
Q1
$159K Buy
+19,242
New +$136K ﹤0.01% 2304
2019
Q3
Sell
-34,959
Closed -$278K 1938
2019
Q2
$278K Sell
34,959
-18,600
-35% -$169K ﹤0.01% 1192
2019
Q1
$550K Buy
+53,559
New +$481K 0.01% 1111

Other funds holding ULBI

Marshall Wace's ULBI Position: Q2 2026 in Review

Marshall Wace increased its Ultralife (ULBI) stake by 121% in Q2 2026, buying an estimated $90.1K and bringing the position to 24,435 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2871.

Marshall Wace first reported a position in ULBI in Q1 2019 and has held it in 14 quarters since. The position peaked at $550K in Q1 2019. 52 funds tracked by Wall St. Rank hold ULBI as of Q2 2026.

  • Marshall Wace held 24,435 shares of Ultralife worth $154K as of Q2 2026.
  • Marshall Wace bought 13,357 Ultralife shares in Q2 2026, an estimated $90.1K.
  • Ultralife made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2871 holding.
  • Marshall Wace first reported a position in Ultralife in Q1 2019 and has held it in 14 quarters since.
  • Marshall Wace's Ultralife position peaked at $550K in Q1 2019.
  • 52 funds tracked by Wall St. Rank held Ultralife as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.